Evidence map›Paper›PMID 29627023›Full record

ArticleJournal of the neurological sciences2018

Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.

Steven A Gunzler, David E Riley, Shu G Chen, Curtis M Tatsuoka, William M Johnson, John J Mieyal, Ellen M Walter, Christina M Whitney, I Jung Feng, Harry Owusu-Dapaah and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the neurological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Steven A GunzlerParkinson's and Movement Disorders Center, Neurological Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, HAN5040, Cleveland, OH 44106, USA. Electronic address: Steven.Gunzler@UHhospitals.org.
David E RileyInMotion, 4829 Galaxy Parkway, Suite M, Warrensville Heights, OH 44128, USA.
Shu G ChenDepartment of Pathology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: shu.chen@case.edu.
Curtis M TatsuokaBiostatistics, Neurological Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, HAN5040, Cleveland, OH 44106, USA. Electronic address: curtis.tatsuoka@case.edu.
William M JohnsonDepartment of Ophthalmology, Duke University School of Medicine, 2608 Erwin Rd, Durham, NC 27705, USA. Electronic address: will.m.johnson@duke.edu.
John J MieyalDepartment of Pharmacology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: jjm5@cwru.edu.
Ellen M WalterParkinson's and Movement Disorders Center, Neurological Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, HAN5040, Cleveland, OH 44106, USA. Electronic address: Ellen.Walter@UHhospitals.org.
Christina M WhitneyParkinson's and Movement Disorders Center, Neurological Institute, University Hospitals Cleveland Medical Center (retired), 11100 Euclid Avenue, HAN5040, Cleveland, OH 44106, USA.
I Jung FengEpidemiology & Biostatistics, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: ixf34@case.edu.
Harry Owusu-DapaahDepartment of Internal Medicine, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA. Electronic address: howusudapaah@metrohealth.org.
Shivam O MittalNeurology, Columbia Asia Hospitals, Sarjapur Road, Bangalore 560035, India.
Amy L Wilson-DelfosseDepartment of Pharmacology, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: axw41@case.edu.
Case Western Reserve University · USUniversity Hospitals of Cleveland · USColumbia Asia · INDuke University · USMetroHealth Medical Center · USUniversity School · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
NCATS NIH HHS UL1 TR000439
6 · The paper itself

Abstract

introductionLRRK2 G2019S mutation carriers with Parkinson's disease (PD) have been generally indistinguishable from those with idiopathic PD, with the exception of variable differences in some motor and non-motor domains, including cognition, gait, and balance. LRRK2 G2019S is amongst the most common genetic etiologies for PD, particularly in Ashkenazi Jewish (AJ) populations.

methodsThis cross-sectional data collection study sought to clarify the phenotype of LRRK2 G2019S mutation carriers with PD. Primary endpoints were the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) and Montreal Cognitive Assessment (MoCA). Other motor and non-motor data were also assessed. The Mann-Whitney U Test was utilized to compare LRRK2 G2019S carriers with PD (LRRK2+) with non-carrier PD controls who were matched for age, gender, education, and PD duration. Survival analyses and log rank tests were utilized to compare interval from onset of PD to development of motor and non-motor complications.

resultsWe screened 251 subjects and 231 completed the study, of whom 9 were LRRK2+, including 7 AJ subjects. 22.73% of AJ subjects with a family history of PD (FH) and 12.96% of AJ subjects without a FH were LRRK2+. There were no significant differences between the 9 LRRK2+ subjects and 19 matched PD controls in MDS-UPDRS, MoCA, or other motor and non-motor endpoints.

conclusionPrevalence of the LRRK2 G2019S mutation in AJ and non-AJ subjects in our study population in Cleveland, Ohio was comparable to other clinical studies. There were no significant motor or non-motor differences between LRRK2+ PD and matched PD controls.

Indexed as

Genetic Predisposition to DiseaseHeterozygoteMutationAgedCross-Sectional StudiesFemaleHumansJewsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleParkinson DiseasePhenotypePilot ProjectsPrevalenceLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanAutosomal dominantCognitionLeucine-rich repeat kinaseMotor featuresNon-motor featuresParkinson's disease

Identifiers

PMID29627023
PMCPMC5908224
OpenAlexW2791170277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.